NCT05086081View on ClinicalTrials.gov

Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data

CompletedOBSERVATIONAL
Enrollment

28,389

Participants

Timeline

Start Date

October 10, 2020

Primary Completion Date

September 10, 2021

Study Completion Date

September 10, 2021

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Ticagrelor 90mg

Any ticagrelor dispensing claim is used as the exposure group

DRUG

Prasugrel 10mg

Any prasugrel dispensing claim is used as the reference group

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT05086081 - Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter